Verve Therapeutics, Inc. (VERV)
|Net Income (ttm)||-53.36M|
|Trading Day||July 27|
|Day's Range||49.05 - 53.49|
|52-Week Range||29.50 - 73.80|
The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $5...
Find out why these stocks are climbing higher.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pr...
Verve Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol i...
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Bl...
VerveTx Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editi... [Read more...]
|IPO Date |
Jun 17, 2021
Sekar Kathiresan, M.D.
|Stock Exchange |
|Ticker Symbol |